Lysteda®, a novel formulation of tranexamic acid, is an antifibrinolytic medication recently approved by the Food and Drug Administration (FDA) for the treatment of heavy menstrual bleeding. Tranexamic acid has been shown to significantly reduce menstrual blood loss while simultaneously allowing a woman to safely become pregnant. The major advantage of Lysteda® (an oral modified-release formulation of tranexamic acid) compared to oral immediate-release tranexamic acid, is the decreased occurrence of gastrointestinal side effects. As there are no therapeutic equivalents to Lysteda® for heavy menstrual bleeding, it is important for pharmacists to be able to counsel patients appropriately on the specific dosing regimen and side effects of this new product.
Schoenberger EB, Tucker TA, Steele JW, Meyer A, Hrometz SL. Lysteda® for Heavy Menstrual Bleeding. PAW Review. 2012 Jul 01; 3(2):Article 2 48-51 . Available from: https://digitalcommons.onu.edu/paw_review/vol3/iss2/2. Free full text article.